Expert Interview
Discussing the standard of care and the potential of AMG 133, a bi-specific GIPR antagonist and glucagon-like peptide-1 (GLP-1) receptor agonist molecule, currently in development by Amgen for the treatment of obesity.
Ticker(s): AMGNInstitution: Northwestern
- Endocrinologist and adjunct professor of medicine (endocrinology) and medical education at Northwestern University Feinberg School of Medicine.
- Manages 20 patients with acromegaly, 15 CAH, and 1000 patients with diabetes (60% on pumps).
- President and Chief Executive Officer of the Accreditation Council for Continuing Medical Education (ACCME).
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
